Scientific article
Open access

Pneumologie: Asthme, mucoviscidose et pression positive nocturne

Published inRevue médicale suisse, vol. 15, no. 632-633, p. 96-100
Publication date2019

In this review of novel therapies in pulmonary disorders in 2018, we cover 3 different entities. In GINA stage 1 and 2 asthma, new strategies allow a more individualized treatment. In more severe asthma, there is an increasing interest in biotherapies, with dupilumab, an anti-IL-4 receptor, completing the already available panel which includes anti-IgE, anti-IL-5 and anti-IL-5 receptor antibodies. In cystic fibrosis, a better understanding of the pathogenesis and the genetics of the disease is leading to new treatments acting directly on the function of the CFTR (Cystic fibrosis transmembrane conductance regulator), which, when used in combination, show very promising results. Finally, nocturnal positive pressure treatment (either CPAP or non invasive ventilation : NIV) is used more and more frequently. Recent studies have clarified therapeutic algorithms for the most frequent indications for NIV : COPD and obesity-hypoventilation.

  • Asthma/therapy
  • Continuous Positive Airway Pressure
  • Cystic Fibrosis/therapy
  • Humans
  • Noninvasive Ventilation
  • Pulmonary Medicine/trends
Citation (ISO format)
PLOJOUX, Jérôme Pierre Olivier, CHARBONNIER, Florian, JANSSENS, Jean-Paul. Pneumologie: Asthme, mucoviscidose et pression positive nocturne. In: Revue médicale suisse, 2019, vol. 15, n° 632-633, p. 96–100.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation11/04/2019 9:00:00 AM
First validation11/04/2019 9:00:00 AM
Update time03/15/2023 6:45:42 PM
Status update03/15/2023 6:45:41 PM
Last indexation01/17/2024 8:47:11 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack